Antidotes for factor Xa inhibitors and methods of using the same
US10954503B2 · kind B2 · utility
1Cited by
32References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 17, 2019 |
| Grant date | Mar 23, 2021 |
| Priority date | — |
| Expiry date | Jan 17, 2039 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K39/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates antidotes to anticoagulants targeting factor Xa. The antidotes are factor X and factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives describe herein lack or have reduced intrinsic coagulant activity. Disclosed herein are methods of reversing anticoagulation, stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.